Genetic Accounts Payable vs Property Plant Equipment Analysis

GTG Stock   0.04  0.00  0.00%   
Genetic Technologies financial indicator trend analysis is much more than just examining Genetic Technologies latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Genetic Technologies is a good investment. Please check the relationship between Genetic Technologies Accounts Payable and its Property Plant Equipment accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Accounts Payable vs Property Plant Equipment

Accounts Payable vs Property Plant Equipment Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Genetic Technologies Accounts Payable account and Property Plant Equipment. At this time, the significance of the direction appears to have no relationship.
The correlation between Genetic Technologies' Accounts Payable and Property Plant Equipment is 0.05. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Property Plant Equipment in the same time period over historical financial statements of Genetic Technologies, assuming nothing else is changed. The correlation between historical values of Genetic Technologies' Accounts Payable and Property Plant Equipment is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Genetic Technologies are associated (or correlated) with its Property Plant Equipment. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant Equipment has no effect on the direction of Accounts Payable i.e., Genetic Technologies' Accounts Payable and Property Plant Equipment go up and down completely randomly.

Correlation Coefficient

0.05
Relationship DirectionPositive 
Relationship StrengthInsignificant

Accounts Payable

An accounting item on the balance sheet that represents Genetic Technologies obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Genetic Technologies are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Property Plant Equipment

Most indicators from Genetic Technologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Genetic Technologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
At this time, Genetic Technologies' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is expected to grow at the current pace this year, whereas Issuance Of Capital Stock is likely to drop slightly above 2.2 M in 2025.
 2022 2023 2024 2025 (projected)
Total Operating Expenses18.1M3.9M3.5M3.3M
Cost Of Revenue4.3M3.8M3.4M1.8M

Genetic Technologies fundamental ratios Correlations

0.17-0.10.980.83-0.9-0.05-0.350.910.21-0.610.91-0.070.21-0.12-0.07-0.31-0.150.330.940.170.21-0.390.010.04-0.44
0.170.480.060.530.190.30.31-0.180.81-0.34-0.180.11-0.290.250.230.00.570.31-0.14-0.240.330.49-0.01-0.07-0.16
-0.10.48-0.260.180.37-0.520.93-0.330.49-0.11-0.330.690.43-0.21-0.19-0.50.880.79-0.260.560.120.29-0.360.180.62
0.980.06-0.260.75-0.940.03-0.50.940.12-0.570.94-0.210.16-0.06-0.03-0.22-0.330.190.950.090.17-0.470.090.01-0.53
0.830.530.180.75-0.58-0.04-0.10.590.55-0.660.60.10.12-0.07-0.05-0.350.190.520.640.120.36-0.09-0.070.03-0.35
-0.90.190.37-0.94-0.580.120.53-1.00.180.5-1.00.25-0.320.270.220.150.42-0.07-0.98-0.220.080.480.03-0.020.52
-0.050.3-0.520.03-0.040.12-0.52-0.150.230.22-0.15-0.5-0.890.770.710.55-0.38-0.62-0.15-0.920.360.070.6-0.36-0.52
-0.350.310.93-0.5-0.10.53-0.52-0.490.240.15-0.50.750.39-0.22-0.17-0.40.870.63-0.430.520.050.34-0.310.060.72
0.91-0.18-0.330.940.59-1.0-0.15-0.49-0.19-0.51.0-0.210.34-0.3-0.25-0.18-0.350.10.990.25-0.08-0.44-0.060.04-0.5
0.210.810.490.120.550.180.230.24-0.19-0.39-0.190.22-0.280.30.21-0.170.40.43-0.14-0.190.470.18-0.04-0.020.04
-0.61-0.34-0.11-0.57-0.660.50.220.15-0.5-0.39-0.51-0.04-0.280.340.410.38-0.09-0.38-0.48-0.260.12-0.10.43-0.010.27
0.91-0.18-0.330.940.6-1.0-0.15-0.51.0-0.19-0.51-0.210.34-0.3-0.25-0.17-0.350.090.990.25-0.08-0.44-0.070.04-0.5
-0.070.110.69-0.210.10.25-0.50.75-0.210.22-0.04-0.210.29-0.21-0.18-0.660.610.67-0.120.430.320.08-0.28-0.240.8
0.21-0.290.430.160.12-0.32-0.890.390.34-0.28-0.280.340.29-0.78-0.73-0.390.280.50.320.98-0.52-0.1-0.580.30.25
-0.120.25-0.21-0.06-0.070.270.77-0.22-0.30.30.34-0.3-0.21-0.780.980.09-0.24-0.2-0.22-0.710.73-0.140.88-0.23-0.12
-0.070.23-0.19-0.03-0.050.220.71-0.17-0.250.210.41-0.25-0.18-0.730.980.06-0.2-0.15-0.15-0.660.76-0.20.94-0.19-0.13
-0.310.0-0.5-0.22-0.350.150.55-0.4-0.18-0.170.38-0.17-0.66-0.390.090.06-0.37-0.85-0.28-0.53-0.420.150.07-0.15-0.56
-0.150.570.88-0.330.190.42-0.380.87-0.350.4-0.09-0.350.610.28-0.24-0.2-0.370.63-0.30.390.060.54-0.40.170.48
0.330.310.790.190.52-0.07-0.620.630.10.43-0.380.090.670.5-0.2-0.15-0.850.630.20.640.36-0.09-0.210.290.5
0.94-0.14-0.260.950.64-0.98-0.15-0.430.99-0.14-0.480.99-0.120.32-0.22-0.15-0.28-0.30.20.260.06-0.490.020.05-0.43
0.17-0.240.560.090.12-0.22-0.920.520.25-0.19-0.260.250.430.98-0.71-0.66-0.530.390.640.26-0.38-0.1-0.550.330.41
0.210.330.120.170.360.080.360.05-0.080.470.12-0.080.32-0.520.730.76-0.420.060.360.06-0.38-0.250.65-0.180.18
-0.390.490.29-0.47-0.090.480.070.34-0.440.18-0.1-0.440.08-0.1-0.14-0.20.150.54-0.09-0.49-0.1-0.25-0.38-0.060.09
0.01-0.01-0.360.09-0.070.030.6-0.31-0.06-0.040.43-0.07-0.28-0.580.880.940.07-0.4-0.210.02-0.550.65-0.38-0.18-0.23
0.04-0.070.180.010.03-0.02-0.360.060.04-0.02-0.010.04-0.240.3-0.23-0.19-0.150.170.290.050.33-0.18-0.06-0.180.06
-0.44-0.160.62-0.53-0.350.52-0.520.72-0.50.040.27-0.50.80.25-0.12-0.13-0.560.480.5-0.430.410.180.09-0.230.06
Click cells to compare fundamentals

Genetic Technologies Account Relationship Matchups

Genetic Technologies fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets23.0M20.8M14.9M6.2M5.6M5.3M
Other Current Liab955.5K1.6M1.3M1.1M1.0M901.4K
Total Current Liabilities1.4M3.8M3.3M4.2M3.8M2.0M
Total Stockholder Equity21.5M16.4M11.2M1.8M1.6M1.6M
Property Plant And Equipment Net637.7K953.3K599.2K264.5K238.0K226.1K
Net Debt(20.7M)(11.1M)(7.3M)(145.4K)(130.9K)(137.4K)
Retained Earnings(143.1M)(150.2M)(156.7M)(166.4M)(149.7M)(142.3M)
Accounts Payable269.7K1.2M838.0K1.5M1.3M789.6K
Cash20.9M11.7M7.9M1.0M1.2M1.1M
Non Current Assets Total735.6K6.1M4.2M2.5M2.2M2.1M
Non Currrent Assets Other(9.5M)(6.1M)(4.2M)81.7K73.5K77.2K
Cash And Short Term Investments20.9M11.7M7.9M1.0M1.2M1.1M
Net Receivables1.1M2.4M191.9K2.1M2.4M2.6M
Common Stock Shares Outstanding85.4M92.2M101.4M132.2M119.0M113.0M
Liabilities And Stockholders Equity23.0M20.8M14.9M6.2M5.6M5.3M
Inventory76.9K398.2K325.9K206.5K185.8K176.5K
Other Stockholder Equity1.2M(10.5M)(4.9M)(4.6M)(4.2M)(4.0M)
Total Liab1.4M4.4M3.7M4.4M3.9M2.3M
Property Plant And Equipment Gross1.3M1.9M1.8M1.5M1.4M946.1K
Total Current Assets22.2M14.7M10.5M3.7M4.2M4.0M
Common Stock153.6M155.1M161.3M163.8M188.4M99.3M
Property Plant Equipment440.2K637.7K953.3K599.2K539.3K876.6K
Short Long Term Debt Total204.0K652.5K532.9K875.2K787.7K509.7K
Other Current Assets182.6K18.2K2.1M341.7K393.0K461.4K
Short Term Debt179.6K264.1K303.6K852.3K980.1K1.0M
Short Term Investments1.9K13.3K17.4K18.8K16.9K16.1K
Non Current Liabilities Total33.3K558.9K381.6K160.6K144.6K137.4K
Accumulated Other Comprehensive Income11.0M11.5M6.5M4.4M5.0M4.3M
Current Deferred Revenue635.0814.2K849.2K741.6K852.9K895.5K
Other Liab979.2K8.9K170.5K152.3K175.2K133.1K
Net Tangible Assets13.0M21.5M11.3M7.5M8.7M11.1M
Long Term Debt Total240.9K24.4K388.4K229.3K263.7K138.8K
Net Invested Capital21.5M16.4M11.2M2.5M2.8M2.7M
Net Working Capital20.8M10.9M7.2M(500.1K)(450.1K)(427.6K)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Genetic Stock Analysis

When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.